Profusa, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Profusa (PFSA) reported progress on conditions for its potential G3 Vision Labs acquisition, but Q2 2026 results showed a widened net loss of $8.8M and limited cash. The company is restructuring its balance sheet with debt-to-equity exchanges. G3's audits are expected by mid-September. PFSA ended June with $719K in cash and $28.2M in liabilities.
Profusa raised $714,285.72 via a senior secured convertible note at 7% interest, maturing in 2027, with a $1.07 conversion price. It also agreed to exchange $6.14M in debt for Series A Preferred Stock, implying a $4.28 conversion price, to simplify its capital structure.
Profusa, Inc. (PFSA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Amendment No. 5 to Securities Purchase Agreement On August 12, 2026, Profusa, Inc., a Delaware corporation (the “Company”), entered into Amendment No. 5 (“Amendment No. 5”) to that certain Securities Purchase Agreement, dated
Over the past 7 days, alphai's AI scored 3 news stories mentioning PFSA (Profusa, Inc.). Coverage has been balanced: 0 bullish, 3 neutral, and 0 bearish.
Recent PFSA coverage spans corporate actions, earnings and financial news.
In the last 30 days, PFSA insiders filed 14 SEC Form 4 transactions — 8 purchases ($37K) and 6 sales ($153K). The most active reporter was HRT FINANCIAL LP with 14 filings.
The acquisition progress could unlock future revenue streams but hinges on audit completion and financing, creating upside risk if completed.
The financing improves capital structure but dilutes equity; short-term price may react modestly.
The note adds a modest amount of senior secured debt and potential dilution if converted, but the size is small relative to the company’s market cap.
Medical‑tech stock slides without disclosed cause.
The widened loss and low cash raise concerns, but the reverse split may stabilize Nasdaq listing and the option agreement could improve future revenue.
alphai scores every news story that mentions PFSA with an AI model for sentiment and relevance, and aggregates insider trades from Profusa, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Profusa (PFSA) reported progress on conditions for its potential G3 Vision Labs acquisition, but Q2 2026 results showed a widened net loss of $8.8M and limited cash. The company is restructuring its balance sheet with debt-to-equity exchanges. G3's audits are expected by mid-September. PFSA ended June with $719K in cash and $28.2M in liabilities.
3 min readProfusa raised $714,285.72 via a senior secured convertible note at 7% interest, maturing in 2027, with a $1.07 conversion price. It also agreed to exchange $6.14M in debt for Series A Preferred Stock, implying a $4.28 conversion price, to simplify its capital structure.
1 min readProfusa, Inc. (PFSA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Amendment No. 5 to Securities Purchase Agreement On August 12, 2026, Profusa, Inc., a Delaware corporation (the “Company”), entered into Amendment No. 5 (“Amendment No. 5”) to that certain Securities Purchase Agreement, dated
1 min readPremarket trading on Friday shows significant moves in several stocks. RFAI surged 489% to $75.00, SUGP rose 46% to $4.04, and USDE climbed 18% to $4.72. Conversely, DFNS dropped 18% to $20.05, OSIS fell 15% to $186.47, and OPHC declined 11% to $8.21. These early swings may indicate momentum for the regular trading session.
1 min readProfusa (PFSA) reported a wider Q2 2026 net loss of $8.8M vs. $2.3M in Q2 2025, with total assets of $1.0M and liabilities of $28.2M. The company expects equity to improve to $28.4M post-option agreement with G3 Vision Labs. PFSA stock is down 40.40% to $8.11.
2 min readProfusa, Inc. (PFSA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company Debt and liabilities holders have executed $10.7 million of Series A Convertible Exchange Agreements; of w
1 min readProfusa (PFSA) CFO Fred Knechtel converted a $1.29M note into 302K shares at $4.28 each, following a 1-for-4 reverse stock split. The conversion occurred on August 12, 2026, under a Note Modification and Conversion Agreement. Knechtel, through NorthView Sponsor I LLC, now indirectly holds 302K shares.
2 min readProfusa (PFSA) sponsor NorthView converted $1.3M debt into 301,991 shares, now owning ~49.9% post reverse stock split. The conversion was per a modified agreement, with shares acquired at $1.07 each.
2 min readProfusa (PFSA) CEO Jack E. Stover converted $1.29M of a Convertible Promissory Note into 301,991 shares of Common Stock, post a 1-for-4 reverse stock split, at $4.28 per share. The conversion occurred on August 12, 2026, as per the Note Modification and Conversion Agreement.
1 min readNorthView Sponsor I, LLC disclosed a 49.9% stake in Profusa, Inc. (PFSA) after converting a $1.29M promissory note into 301,991 shares, following a 1-for-4 reverse stock split. The sponsor has significant voting influence, with managers Jack Stover and Fred Knechtel sharing authority over the stake.
1 min read
